Event > Conference >
MPS World Summit Berlin 2023
After a very successful inaugural conference in New Orleans, the MPS World Summit is in Europe. Organized by the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) and EUROoCS, with the support of more than forty organizations, is proud to present the Microphysiological Systems World Summit.
Head to our exhibition stand – #1414
Our dedicated team of creative problem solvers will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you!
We look forward to meeting you to discuss how our PhysioMimix® range of products and services can help to improve the predictivity of your toxicology workflows and address your current workflow limitations – such as modelling the immune system in vitro and testing the safety of new modality drugs with human-specific modes of action.
Get familiar with our human-relevant single- and multi-organ in vitro models and learn more about their proven track record for delivering clinically translatable results, plus meet the new game-changing product in our PhysioMimix OOC range of microphysiological systems!
Organ-on-a-chip Workshop
Keeping it real: Overcoming the challenges of generating translational pre-clinical liver toxicology data
Adverse drug reactions remain a major cause of drug failures. Standard preclinical approaches are poorly predictive, particularly for molecules with human-specific toxicity. Liver-on-a-chip cocultures of primary hepatocytes accurately recapitulate organ-level functionality to better predict acute and chronic human drug toxicity.
Date: Tuesday, June 26, 2023
Time: 12:00 – 15:30 PM
Room: Salon 21
Presentation from: Dr Atefeh Mobasseri, CN Bio
Podium presentations
A PK/PD translational microphysiological system to explore anti-cancer therapies efficacy on 3D tumour spheroids and patient derived organoids
Our MPS platform is able to mimic animal and human PK profiles thus potentially avoiding many failures of novel therapies which are due to a missing physiologically relevant link between preclinical and clinical data. By tailoring individualized PK profiles and therapeutic schedules, we introduce a valuable tool and strategy in the pursuit of personalized medicine for the treatment of cancer.
Date: TBC
Time: 12:00 PM
Room: 101B
Presentation from: Dr Tudor Petreus, CN Bio
Communication is key: exploring local and systemic inflammatory responses to infection using a multi-organ lung-liver-immune axis microphysiological system
Prolonged inflammation due to infection can result in excessive release of inflammatory markers and ultimately inter-organ dysfunction or disease. Pneumonia or sepsis from severe pulmonary infections cause hepatic acute-phase response (APR) which is largely induced by IL-6 signalling. The cytokine storm associated with COVID-19 disease in particular is characterised by high expression of TNFα and IL-6 which has been shown to negatively impact liver function. Here, this phenomenon is demonstrated using the CN Bio PhysioMimix Dual-Organ system to coculture lung and liver microtissues with circulating monocytes. Together, this MPS system allows novel and data-rich insights into both local and systemic response to infection. Greater understanding of pathogens’ interaction with the body can be elucidated, allowing for more rapid and targeted drug development approaches in the future to reduce severe disease and death from both current and future novel pathogens.
Date: Wednesday, June 27, 2023
Time: 2:30-4:30 PM (3:30-3:40 PM)
Room: Salon 21
Session: 3.2 Lung Disease Models
Presentation from: Dr Emily Richardson, CN Bio
CN Bio posters
Connecting the human intestine and liver: a primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability
Poster Board:
Presentation from: CN Bio & Altis
Bridging the gap – how human microphysiological systems improve the translatability of NASH Drug Discovery
Poster Board: 30
Abstract: 278
Presentation from: Raul Silva, CN Bio
Customer posters citing the use of PhysioMimix OOC
Bayer
Details to follow.
Poster Board:
Presentation from:
Liverpool School of Tropical Medicine
Details to follow.
Poster Board:
Presentation from:
Our Team at MPS
Paul
Dr Paul Brooks is CEO at CN Bio, having joined in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Deepak
Deepak Singh joined CN Bio in February 2023, and we are excited that he will join us at another world-leading conference in just his second month. He has over 30 years of commercial experience within the life science industry. Deepak has been key in leading high-performance sales, support & marketing teams in establishing new technologies. Working with his teams, he has driven the global scalability of products & solutions into the markets in drug discovery, bioproduction, research and diagnostics. Deepak studied at the Polytechnic of Central London and gained a Bsc in Biotechnology.
Adrian
Dr Adrian Rea is a seasoned business developer with extensive commercial experience in the life science sector, Adrian joined CN-Bio Innovations as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.
Audrey
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Vaish
Vaishnavi Manoharan-Jayarajah is an Account Manager at CN Bio with 5+ years of experience handling key accounts within the Biopharma and research industries globally. Vaish has been with CN Bio for over 3 years with consultative sales experience with instruments and services. Prior to joining CN Bio, Vaish was an Education Associate and Lab Manager at STEMCELL Technologies. She graduated with a Biomedical Science degree and holds a Masters in Immunology from Imperial College London.
Atefeh
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimixTM systems to generate high content, human-relevant, data.
Parham
Dr Parham Ashrafzadeh is the UK/Nordics Account Manager at CN Bio and is based in London. Parham helps scientists within academia, biotech and pharma sectors to find the best solutions for testing their therapeutics which are more cost effective, clinically relevant and safer at the drug discovery stage. Parham holds a PhD from Uppsala University in Sweden and completed a collaborative postdoctoral fellowship between four universities around the globe.
Raul
Raul Silva is a Scientist working in CN Bio’s Contract Research team. Before joining CN Bio, Raul was a genetic technologist at the Cambridge University Hospitals Genomics Laboratory, working in genetic diagnostic testing. He has a background in genomics and cell biology, having completed a BSc in biomedical science at Anglia Ruskin University and an MSc in cell and gene therapy at University College London. Since joining CN Bio, Raul has had an active role in delivering contract research projects using the PhysioMimix™ OOC microphysiological systems and has become a specialist in CN Bio’s NASH model used to assess anti-NASH compounds efficacy.